PD-1 Ab naïve (n=6) | PD-1 Ab experienced (n=16) | All participants (n=22) | |
Complete response | 1 (16.7%) (0.4% to 64.1%) | 0 (0.0% to 20.6%) | 1 (4.5%) (0.1% to 22.8%) |
Partial response | 3 (50.0%) (11.8% to 88.2%) | 1 (6.2%) (0.2% to 30.2%) | 4 (18.2%) (5.2% to 40.3%) |
Stable disease | 0 (0.0% to 45.9%) | 4 (25%) (7.3% to 52.4%) | 4 (18.2%) (5.2% to 40.3%) |
Progressive disease | 2 (33.3%) (4.3% to 77.7%) | 11 (68.8%) (41.3% to 89.0%) | 13 (59.1%) (36.4% to 79.3%) |
Number progression-free | 2 (33.3%) (4.3% to 77.7%) | 0 (0.0% to 20.6%) | 2 (9.1%) (1.1% to 29.2%) |
Number alive | 4 (66.7%) (22.3% to 95.7%) | 2 (12.5%) (1.6% to 38.4%) | 6 (27.3%) (10.7% to 50.2%) |
Number of participants, % of total, (95% CI).